CN104262204A - Preparation method of guanidine salicylate compound - Google Patents
Preparation method of guanidine salicylate compound Download PDFInfo
- Publication number
- CN104262204A CN104262204A CN201410482661.2A CN201410482661A CN104262204A CN 104262204 A CN104262204 A CN 104262204A CN 201410482661 A CN201410482661 A CN 201410482661A CN 104262204 A CN104262204 A CN 104262204A
- Authority
- CN
- China
- Prior art keywords
- preparation
- ointment
- whitfield
- guanidine
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a preparation method of a guanidine salicylate compound. The preparation method comprises the following concrete steps of adding salicylic acid into an organic solvent to sufficiently dissolve under the condition of water bath; then, slowly adding guanidine carbonate into the solution under the condition of stirring, and continuing to stir after adding all the guanidine carbonate; and next, cooling, filtering, concentrating filtrate to be dry, and placing the dry product into a 60-DEG C drying oven to continue to dry to obtain a white solid guanidine salicylate compound, wherein the reaction is carried out at the temperature of 25-75 DEG C for 0.5-10 hours, and the molar ratio of the added guanidine carbonate to salicylic acid is 1:1 to 1:5. The preparation method is simple and convenient to operate and suitable for industrial production; the dosage of the organic solvent is small, so that excessive organic solvent residues are avoided, and the medication safety is ensured; salicylic acid and guanidine carbonate are stable in character and sufficient in reaction, so that the yield is relatively high; and the preparation method is simple, low in cost and free of environment pollution.
Description
Technical field
The present invention relates to a kind of preparation method of Whitfield's ointment guanidine compound, belong to Chemicals preparing technical field.
Background technology
Whitfield's ointment is a kind of fat-soluble organic acid, so it easily can disintegrate the unnecessary sebum of skin surface, suppress sebum excessive secretion simultaneously, also stronger solvency action is had for the keratotic plug formed because of sebum blocking, small pox, improve the unclean state of follicular wall, help sebum to get rid of smoothly from pore, receive dry small pox fast by antibacterial characteristic simultaneously.Whitfield's ointment can material for connecting between dissolved cell and cell, makes aging cutin cell from skin surface fast-falling, thus promotes the metabolism of skin, recover the sense of touch that skin is careful.The pigment deposition of skin surface usually occurs in unsound keratinocyte layer, use Whitfield's ointment can help to peel off this one deck aging cutin cell, just as mirror be easily wiped clean after again recover bright and clear impression clearly.In addition, Whitfield's ointment can assist the infiltration of other acids whitening compositions.Whitfield's ointment mainly serves as cosmetics preservative, is also used for the raw material of medicine industry, and clinical conventional Salicylates mainly contains Asprin, sodium salicylate, salicylic amide, ethoxybenzamide, salol, Niclosamide etc. at present.
Along with Salicylates application more prevalent, increasing untoward reaction is also exposed, wherein outstanding with salicylic acid toxic reaction.Salicylates is poisoning mostly to be caused by the excessive or long-term extensive application of ampoule, more easily wrongly takes excessive mishap at cradle.External application Whitfield's ointment ointment or powder class, can through dermal tokicities in widespread skin breakage.Having dehydration, Liver and kidney function is incomplete, and serious toxicity reaction occurs the patient Geng Yi of Hypoprothrombinemia.Salicylate can through placental barrier, pregnant woman's overdose, often causes fetus or newborn infant is poisoning.
Therefore, suitable structural modification is carried out to Whitfield's ointment, suitable to obtaining clinical efficacy, and the novel cpd that side effect is less, seem particularly important, be of great immediate significance and good application prospect.
Summary of the invention
Technical problem to be solved by this invention is, provides the preparation method of the Whitfield's ointment guanidine compound that a kind of clinical efficacy is suitable, side effect is little.
For solving the problems of the technologies described above, the technical solution used in the present invention is:
A kind of preparation method of Whitfield's ointment guanidine compound, it is characterized in that, concrete steps are: under water bath condition, Whitfield's ointment is joined in organic solvent and fully dissolves, then in solution, slowly Guanidinium carbonate is added when stirring, all add rear continuation to stir, then after cooling, filtering, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine off-white color solid chemical compound, temperature of reaction is 25-75 DEG C, reaction times is 0.5-10h, and described Guanidinium carbonate and the salicylic mol ratio that adds are 1:1-1:5.
Further, described organic solvent is any one in ethanol, methyl alcohol, ether.
And described organic solvent is preferably ethanol.
Described temperature of reaction is preferably 45-65 DEG C.The described reaction times is preferably 0.5-2h., and described Guanidinium carbonate and the salicylic mol ratio that adds are preferably 1:2.
Beneficial effect of the present invention is: the present invention is easy and simple to handle, is suitable for suitability for industrialized production; Organic solvent uses few, avoids too much organic solvent residual, ensures drug safety; Whitfield's ointment and Guanidinium carbonate stable in properties, sufficient reacting, yield is higher; Preparation method is simple, the low and non-environmental-pollution of cost.
Embodiment
Provide specific embodiments of the invention below, describe technical characteristic of the present invention in detail.
embodiment 1:
Under 45 DEG C of water-baths, 1mol Whitfield's ointment to be joined in the ethanol of 200ml stirring and dissolving fully after, slowly add 2mol Guanidinium carbonate wherein, limit edged stirs, all add rear continuation stirring reaction 1 hour, after cooling, filtration, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine compound compound as white solid.
embodiment 2:
Under 60 DEG C of water-baths, 1mol Whitfield's ointment to be joined in the methyl alcohol of 200ml stirring and dissolving fully after, slowly add 4mol Guanidinium carbonate wherein, limit edged stirs, all add rear continuation stirring reaction 4 hours, after cooling, filtration, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine compound compound as white solid.
embodiment 3:
Under 45 DEG C of water-baths, 1mol Whitfield's ointment to be joined in the ethanol of 200ml stirring and dissolving fully after, slowly add 4mol Guanidinium carbonate wherein, limit edged stirs, all add rear continuation stirring reaction 8 hours, after cooling, filtration, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine compound compound as white solid.
embodiment 4:
Under 25 DEG C of water-baths, 1mol Whitfield's ointment to be joined in the ethanol of 200ml stirring and dissolving fully after, slowly add 3mol Guanidinium carbonate wherein, limit edged stirs, all add rear continuation stirring reaction 6 hours, after cooling, filtration, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine compound compound as white solid.
Above-described embodiment gained compound as white solid is the knowledge analysis and bound drug chemistry is correlated with through mass spectrum, and its structural formula is as follows:
。
The above is only the preferred implementation of patent of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from patent principle of the present invention; can also make some improvements and modifications, these improvements and modifications also should be considered as the protection domain of patent of the present invention.
Claims (6)
1. the preparation method of a Whitfield's ointment guanidine compound, it is characterized in that, concrete steps are: under water bath condition, Whitfield's ointment is joined in organic solvent and fully dissolves, then in solution, slowly Guanidinium carbonate is added when stirring, all add rear continuation to stir, then after cooling, filtering, filtrate is concentrated into dry, and be placed in continuation oven dry in 60 DEG C of loft drier, obtain Whitfield's ointment guanidine off-white color solid chemical compound, temperature of reaction is 25-75 DEG C, reaction times is 0.5-10h, and described Guanidinium carbonate and the salicylic mol ratio that adds are 1:1-1:5.
2. the preparation method of a kind of Whitfield's ointment guanidine compound according to claim 1, is characterized in that, described organic solvent is any one in ethanol, methyl alcohol, ether.
3. the preparation method of a kind of Whitfield's ointment guanidine compound according to claim 1, is characterized in that, described organic solvent is ethanol.
4. the preparation method of a kind of Whitfield's ointment guanidine compound according to claim 1, is characterized in that, described temperature of reaction is 45-65 DEG C.
5. the preparation method of a kind of Whitfield's ointment guanidine compound according to claim 1, is characterized in that, the described reaction times is 0.5-2h.
6. the preparation method of a kind of Whitfield's ointment guanidine compound according to claim 1, is characterized in that, described Guanidinium carbonate and the salicylic mol ratio that adds are 1:2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482661.2A CN104262204A (en) | 2014-09-22 | 2014-09-22 | Preparation method of guanidine salicylate compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482661.2A CN104262204A (en) | 2014-09-22 | 2014-09-22 | Preparation method of guanidine salicylate compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104262204A true CN104262204A (en) | 2015-01-07 |
Family
ID=52153824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410482661.2A Pending CN104262204A (en) | 2014-09-22 | 2014-09-22 | Preparation method of guanidine salicylate compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104262204A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114436898A (en) * | 2020-11-02 | 2022-05-06 | 田雨 | Production process of guanidine sulfate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158606A (en) * | 1994-08-05 | 1997-09-03 | 藤泽药品工业株式会社 | Benzoylaguanidine derivatives as medicaments |
| CN1819989A (en) * | 2003-07-07 | 2006-08-16 | 宝洁公司 | 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof |
| CN102093261A (en) * | 2009-12-14 | 2011-06-15 | 中国药科大学 | Salicylic acid metformin salt and preparation method and medical application thereof |
| JP2013056836A (en) * | 2011-09-07 | 2013-03-28 | Jts Inc | Cosmetic material for hair |
| US20130252926A1 (en) * | 2011-05-11 | 2013-09-26 | Banavara L. Mylari | Metformin salts of salicylic acid and it congeners |
-
2014
- 2014-09-22 CN CN201410482661.2A patent/CN104262204A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158606A (en) * | 1994-08-05 | 1997-09-03 | 藤泽药品工业株式会社 | Benzoylaguanidine derivatives as medicaments |
| CN1819989A (en) * | 2003-07-07 | 2006-08-16 | 宝洁公司 | 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof |
| CN102093261A (en) * | 2009-12-14 | 2011-06-15 | 中国药科大学 | Salicylic acid metformin salt and preparation method and medical application thereof |
| US20130252926A1 (en) * | 2011-05-11 | 2013-09-26 | Banavara L. Mylari | Metformin salts of salicylic acid and it congeners |
| JP2013056836A (en) * | 2011-09-07 | 2013-03-28 | Jts Inc | Cosmetic material for hair |
Non-Patent Citations (1)
| Title |
|---|
| 韦长梅: "胍基化合物的合成与晶体结构研究", 《中国优秀硕博士学位论文全文数据库(博士)工程科技I辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114436898A (en) * | 2020-11-02 | 2022-05-06 | 田雨 | Production process of guanidine sulfate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104262204A (en) | Preparation method of guanidine salicylate compound | |
| CN101139280B (en) | Preparation method of sodium acetate anhydrous | |
| CN104327129A (en) | Method for preparing glucosamine hydrochloride by taking crab shells as raw materials | |
| CN104830281B (en) | A kind of medium temperature composite shape-setting phase-change heat-storage material and preparation method thereof | |
| CN102952119B (en) | Sodium rabeprazole preparation method | |
| CN104326512B (en) | A kind of preparation method of nickelous fluoride | |
| CN103880776A (en) | Method for preparing 2-amino-5-alkyl-1,3,4-thiadiazole | |
| CN105732357A (en) | 2-chloro-4-fluorobenzoic acid and preparation method thereof | |
| CN104356043A (en) | Method for preparing 5-(2-fluorophenyl)-1H-pyrryl-3-formaldehyde | |
| CN104774158A (en) | Novel preparation method for ornithine aspartate | |
| CN105418507A (en) | Preparation method for 1-(3-methyl-1-phenyl-1H-pyrazole-5-yl)piperazine | |
| CN103265586B (en) | A kind of method being prepared Lauryl.beta.-maltoside by maltose | |
| CN107325078B (en) | Preparation method of cilostazol | |
| CN106866493B (en) | A kind of preparation method of Apremilast | |
| CN105418484A (en) | Preparation method of 3-formyl(acetyl)-N-alkyl carbazole semicarbazide (thiosemicarbazide) Schiff base | |
| CN105601580B (en) | The synthetic method of Yi Zhong oxazole class pharmaceutical intermediate compounds | |
| CN102887838A (en) | Preparation method of guanfacine hydrochloride | |
| CN103539733A (en) | Preparation method of isoniazid para-aminosalicylate | |
| RU2011128605A (en) | A WATER-SOLUBLE MOLECULAR COMPLEX OF INCLUSION OF THE RESTORED FORM OF Q10 COENZYM IN β-CYCLODEXTRIN AND METHOD OF ITS PREPARATION | |
| CN105218546B (en) | Synthesis process of 1H-pyrrolo[2,3-B] pyridine-3-carboxylic methyl ether | |
| CN102417446B (en) | Production method for zinc undecylenate | |
| CN105111122A (en) | Method for synthesizing and purifying benzoyl peroxide | |
| CN105481732B (en) | A kind of three component eutectic ionic liquids based on inner salt | |
| CN102936238B (en) | New crystal form of S-omeprazole magnesium salt and preparation method thereof | |
| CN103483337B (en) | Fluorinated isoquinoline [a] pyrrole compounds and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |